Park I, Lee JL, Lee S-HL. Axitinib for recurrent or metastatic non-clear cell renal cell carcinoma. EMUC 2017, P105.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024
jul 2024
jun 2024
mrt 2024